{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:24Z","timestamp":1791273204939,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.iac.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:31Z","timestamp":1787744611000},"page":"723-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["With Great Power Comes Great Responsibility"],"prefix":"10.1016","volume":"46","author":[{"given":"Katherine Quinn Newman","family":"Hudson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli W.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41576-023-00656-z","article-title":"Inborn errors of immunity: an expanding universe of disease and genetic architecture","volume":"25","author":"Akalu","year":"2024","journal-title":"Nat Rev Genet"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000534575","article-title":"Infectious disease screening prior to systemic immunomodulatory therapy in hidradenitis suppurativa: Consensus guidelines from the Asia-Pacific Hidradenitis Suppurativa foundation","volume":"240","author":"Kozera","year":"2024","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.iac.2026.06.012_bib4","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib5","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.iac.2026.06.012_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant Zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on immunization practices - united States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines12010082","article-title":"Vaccinations in selected immune-related diseases treated with biological drugs and JAK inhibitors-literature review and statement of experts from Polish dermatological Society","volume":"12","author":"Narbutt","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and immunology","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib10","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41271-6","article-title":"Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study","volume":"13","author":"Winkelmann","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.iac.2026.06.012_bib12","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2021-220435","article-title":"B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner","volume":"80","author":"Graalmann","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.iac.2026.06.012_bib13","article-title":"B-cell targeted therapeutics in clinical development","volume":"15 Suppl 1","author":"Bl\u00fcml","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.iac.2026.06.012_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-13-317","article-title":"Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study","volume":"13","author":"Lanini","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.iac.2026.06.012_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2010-0106","article-title":"Hepatitis B reactivation and rituximab in the oncology practice","volume":"15","author":"Villadolid","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.iac.2026.06.012_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2169\/internalmedicine.56.7468","article-title":"Late reactivation of hepatitis B virus after chemotherapies for hematological malignancies: a case report and review of the literature","volume":"56","author":"Yamada","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.iac.2026.06.012_bib17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.iac.2026.06.012_bib18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.iac.2026.06.012_bib19","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.iac.2026.06.012_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2011.10.005","article-title":"B-cell therapies in established rheumatoid arthritis","volume":"25","author":"Leandro","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.iac.2026.06.012_bib22","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib23","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib26","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1002\/art.34564","article-title":"Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus","volume":"64","author":"Merrill","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.iac.2026.06.012_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.iac.2026.06.012_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib29","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"issue":"suppl","key":"10.1016\/j.iac.2026.06.012_bib30","article-title":"No clinically meaningful impact of remibrutinib on mean immunoglobulin levels or infections in chronic spontaneous urticaria","volume":"65","author":"B\u00e9rard","year":"2025","journal-title":"Rev Fr Allergol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib33","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.iac.2026.06.012_bib34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2026.06.012_bib35","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.3324\/haematol.2017.187070","article-title":"Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia","volume":"103","author":"Martinelli","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib36","doi-asserted-by":"crossref","first-page":"e00035-19","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"22","key":"10.1016\/j.iac.2026.06.012_bib37","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.iac.2026.06.012_bib38","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of Abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.iac.2026.06.012_bib41","article-title":"Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11886-021-01621-0","article-title":"Rilonacept (Interleukin-1 inhibition) for the treatment of pericarditis","volume":"24","author":"Wang","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.iac.2026.06.012_bib43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.iac.2026.06.012_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12325-022-02322-y","article-title":"No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.iac.2026.06.012_bib47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.iac.2026.06.012_bib48","author":"Tarrytown"},{"issue":"2","key":"10.1016\/j.iac.2026.06.012_bib49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.iac.2026.06.012_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.iac.2026.06.012_bib51","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient years of exposure","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.iac.2026.06.012_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/ijd.IJD_233_16","article-title":"Secukinumab - first in class Interleukin-17A inhibitor for the treatment of psoriasis","volume":"62","author":"Godse","year":"2017","journal-title":"Indian J Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2026.06.012_bib53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2026.06.012_bib54","series-title":"StatPearls [Internet]","article-title":"Brodalumab","author":"Golbari","year":"2025"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of Ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib56","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti interleukin 17A monoclonal antibody, in patients with moderate to severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2026.06.012_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.012_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"24","author":"Koo","year":"2010","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2026.06.012_bib60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.iac.2026.06.012_bib62","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: a clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib63","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.iac.2026.06.012_bib65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"9038","key":"10.1016\/j.iac.2026.06.012_bib66","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate mofetil","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"issue":"8\u20139","key":"10.1016\/j.iac.2026.06.012_bib67","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1081\/NCN-200027360","article-title":"Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites","volume":"23","author":"Dijkmans","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl 8","key":"10.1016\/j.iac.2026.06.012_bib68","first-page":"S117","article-title":"Therapy of rheumatoid arthritis with mycophenolate mofetil","volume":"11","author":"Goldblum","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.iac.2026.06.012_bib69","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00296-015-3265-6","article-title":"Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus","volume":"35","author":"Subedi","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.iac.2026.06.012_bib70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.82.4.423","article-title":"Ocular complications of heart, lung and liver transplantation","volume":"82","author":"Ng","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.012_bib71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1034\/j.1399-0012.2000.140206.x","article-title":"Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients","volume":"14","author":"Sarmiento","year":"2000","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.iac.2026.06.012_bib72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1399-0012.1998.tb01091.x","article-title":"Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses","volume":"12","author":"Moreso","year":"1998","journal-title":"Clin Transpl"},{"issue":"31","key":"10.1016\/j.iac.2026.06.012_bib73","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.3748\/wjg.14.4849","article-title":"Cytomegalovirus infection after liver transplantation: current concepts and challenges","volume":"14","author":"Razonable","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2018","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.iac.2026.06.012_bib75","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.iac.2026.06.012_bib76","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.MIB.0000160742.91602.b7","article-title":"Methods to avoid infections in patients with inflammatory bowel disease","volume":"11","author":"Aberra","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.iac.2026.06.012_bib77","first-page":"47","article-title":"Incidence of Pneumocystis jirovecii Pneumonia and prophylaxis-associated adverse events among patients with systemic lupus erythematosus","volume":"52","author":"Jiang","year":"2025","journal-title":"J Rheumatol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:26:44Z","timestamp":1791271604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0889856126000676"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.012","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"With Great Power Comes Great Responsibility","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}